A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

(2018) Bruno Gomes et al.   MOLECULAR CANCER THERAPEUTICS

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate

(2017) Stefano Crosignani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan

(2015) N. van Baren et al.   Cancer Immunology Research

High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2014) R. Stupp et al.   ANNALS OF ONCOLOGY

The epidemiology of glioma in adults: a "state of the science" review

(2014) Q. T. Ostrom et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Expression of Indoleamine 2,3-Dioxygenase and Correlation With Pathological Malignancy in Gliomas

(2013) Kentaro Mitsuka et al.   NEUROSURGERY

IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival

(2012) D. A. Wainwright et al.   CLINICAL CANCER RESEARCH

Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors

(2012) S. Lancellotti et al.   CURRENT MEDICINAL CHEMISTRY

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

(2011) Christiane A. Opitz et al.   NATURE

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY